209 related articles for article (PubMed ID: 29536182)
1. Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
Gupta B; Poudel BK; Regmi S; Pathak S; Ruttala HB; Gautam M; An GJ; Jeong JH; Choi HG; Yong CS; Kim JO
Pharm Res; 2018 Mar; 35(5):96. PubMed ID: 29536182
[TBL] [Abstract][Full Text] [Related]
2. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
4. Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy.
Khatri H; Chokshi N; Rawal S; Patel BM; Badanthadka M; Patel MM
Int J Pharm; 2020 Jun; 583():119386. PubMed ID: 32376440
[TBL] [Abstract][Full Text] [Related]
5. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib complexation with randomly methylated
Erdoğar N; Akkın S; Varan G; Bilensoy E
Pharm Dev Technol; 2021 Sep; 26(7):797-806. PubMed ID: 34219578
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.
Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X
Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
10. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma.
Lollo G; Vincent M; Ullio-Gamboa G; Lemaire L; Franconi F; Couez D; Benoit JP
Int J Pharm; 2015 Nov; 495(2):972-80. PubMed ID: 26428632
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells.
Bruinsmann FA; Buss JH; Souto GD; Schultze E; de Cristo Soares Alves A; Seixas FK; Collares TV; Pohlmann AR; Guterres SS
AAPS PharmSciTech; 2020 Aug; 21(6):229. PubMed ID: 32778976
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
[TBL] [Abstract][Full Text] [Related]
13. PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer.
Phung CD; Le TG; Nguyen VH; Vu TT; Nguyen HQ; Kim JO; Yong CS; Nguyen CN
Pharm Res; 2020 Jun; 37(7):129. PubMed ID: 32548664
[TBL] [Abstract][Full Text] [Related]
14. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
15. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy.
Wang G; Wang Z; Li C; Duan G; Wang K; Li Q; Tao T
Biomed Pharmacother; 2018 Oct; 106():275-284. PubMed ID: 29966971
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance.
Zhang W; Shi Y; Chen Y; Yu S; Hao J; Luo J; Sha X; Fang X
Eur J Pharm Biopharm; 2010 Aug; 75(3):341-53. PubMed ID: 20451605
[TBL] [Abstract][Full Text] [Related]
17. Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel.
Sahu PK; Mishra DK; Jain N; Rajoriya V; Jain AK
Drug Dev Ind Pharm; 2015 Apr; 41(4):640-9. PubMed ID: 24564799
[TBL] [Abstract][Full Text] [Related]
18. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Chen S; Zhang Z; Zhang J
Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
[No Abstract] [Full Text] [Related]
19. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Kirschbrown W; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1025-32. PubMed ID: 26420235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
